Lamotrigine for the treatment of epilepsy in childhood
F M Besag1, S J Wallace, O Dulac
1Centre for Epilepsy, London, England, United Kingdom.
Insights
Lamotrigine effectively treated epilepsy in children, showing significant seizure reduction, especially for absence and atonic seizures. This antiepileptic drug demonstrated good tolerability in pediatric patients.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Epilepsy affects a significant number of children worldwide.
- Treatment-resistant epilepsy in pediatric populations presents a therapeutic challenge.
- Evaluating novel antiepileptic drugs in children is crucial for improving patient outcomes.
Purpose of the Study:
- To assess the efficacy and tolerability of lamotrigine in children under 13 with treatment-resistant epilepsy.
- To determine the effectiveness of lamotrigine across various seizure types in pediatric patients.
Main Methods:
- Multicenter, open-label, add-on design.
- Pooled data analysis from five distinct studies.
- Inclusion of 285 children with treatment-resistant epilepsy, often with multiple seizure types.
Main Results:
- One-third of patients experienced a 50% or greater reduction in seizure frequency.
- Lamotrigine demonstrated efficacy across all seizure types, notably for absence and atonic seizures.
- Common adverse experiences included somnolence and rash; 12.6% of patients withdrew due to adverse events.
Conclusions:
- Lamotrigine is a well-tolerated and effective antiepileptic medication for a wide spectrum of seizure types in children.
- The drug shows particular promise for managing absence and atonic seizures in pediatric epilepsy.
- Dosage adjustments are necessary based on concomitant valproate use.
Objective:
In this multicenter study, the efficacy and tolerability of lamotrigine were assessed in 285 children less than 13 years of age, recruited from 37 centers in 11 countries.
Methods:
Pooled data from five open add-on studies have been analyzed. All the children had treatment-resistant epilepsy and most had two or more seizure types. Seizure frequency and global evaluation were assessed at the end of four successive 12-week periods of therapy.
Results:
Seizure frequency was reduced by 50% or more in one third of the patients. Lamotrigine was effective in all seizure types examined, particularly for typical and atypical absence seizures. Atonic seizures also responded well. Improvement was well maintained during the treatment period. The maintenance dose had to be adjusted according to concomitant medication; dose ranges were 1 to 5 mg/kg per day for children taking valproate and 5 to 15 mg/kg per day for those not taking valproate. The commonest reported adverse experiences were somnolence, rash, vomiting, and seizure exacerbations. Adverse experiences led to withdrawal of treatment from 36 patients (12.6%).
Conclusions:
These results indicate that lamotrigine is well tolerated and is effective for a broad range of seizure types, especially absence seizures and atonic seizures.
More Related Videos
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...